Home
Scholarly Works
THRIVE I: Efficacy and tolerability of the novel,...
Conference

THRIVE I: Efficacy and tolerability of the novel, oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis.

Authors

Schulman S; Wahlander K; Gustafsson D; Welin L; Frison L; Eriksson H

Volume

98

Pagination

pp. 447A-448A

Publisher

AMER SOC HEMATOLOGY

Publication Date

November 16, 2001

Conference proceedings

BLOOD

Issue

11

ISSN

0006-4971

Contact the Experts team